BMCC-2022-STU06-1

Minimal Residual Disease (MRD) Detection of NSCLC with Microfluidic-Capture Microdissection (MCM) System

BMCC

The SACA system, which utilizes a variety of technology including a dynamic Live- cell Staining Microdialysis Chip and Patient-Derive Explants Platform used for profiling, allows for more efficient response assessment and selection for cancer immunotherapy. We developed a Microfluidic-capture Microdissection (MCM) system for single cell isolation based on nondestructive sampling, providing highly customized & quality total solutions to procure subpopulations of live tissue cells or PMBC in blood.

未定中標題
BMCC Targeted indication

Monitoring immune responses in the tumor microenvironment

BMCC Status

Prototype platform of Microfluidic-capture Microdissection (MCM) for validation of the possibility of Minimal residual disease (MRD) in NSCLC

BMCC Key features
  • Realtime monitoring of tumor associated macrophage
  • Microdissection the desired cell in a targeted group
  • Keep all targeted tumor cells are viability for RNAseq
BMCC Market

MODE OF ACTION

EXPERIMENTAL RESULTS

Target Verification

Proof of IEC61010-1 &61326-1

Target Validation

In clinical performance study with China Medical University Hsinchu Hospital

Clinical Validation

Plan to start the clinical trials (pivotal studies) at 2024 Q1

Description

On the way of building up the SOP of MRD processing that ruled by FDA draft guidance to assist with the use of minimal residual disease as a biomarker of tumor burden quantification

INTELLECTUAL PROPERTY

8 patents (US(2), TW(4), PCT(2))

SELECTED PUBLICATIONS

17+ Journal papers

BUSINESS OPPORTUNITY

✓ IO combination therapies dynamic monitoring.
✓ Spatial Heterogeneity.
✓ Intratumoral heterogeneity.
✓ Co-development with strategy partners is focused on improving the ORR by dynamic monitoring immune responses in the tumor microenvironment

CONTACT

service@biip-dcc.org

*欲下載完整檔案請 登入/ 會員註冊